ImmunoCellular Therapeutics (IMUC) 10-Q 7 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Document Document And Entity Information [Line Items]	'	'
Entity Registrant Name	'ImmunoCellular Therapeutics, Ltd.	'
Entity Central Index Key	'0000822411	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	57,095,788

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$29,433,560	$26,216,668
Other assets	401,962	714,508
Total current assets	29,835,522	26,931,176
Property and equipment, net	74,667	76,289
Deposits	28,844	11,736
Total assets	29,939,033	27,019,201
Current liabilities:	'	'
Accounts payable	554,743	732,851
Accrued compensation and benefits	296,262	309,345
Accrued expenses	216,524	56,111
Total current liabilities	1,067,529	1,098,307
Warrant liability	3,690,609	2,852,880
Commitments and contingencies (Note 5)	'	'
Shareholders’ equity:	'	'
Common stock, $0.0001 par value; 149,000,000 shares and 99,000,000 shares authorized as of September 30, 2013 and 2012, respectively; 56,625,294 shares and 51,500,996 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively	5,663	5,150
Additional paid-in capital	77,261,623	66,231,694
Deficit accumulated during the development stage	-52,086,391	-43,168,830
Total shareholders’ equity	25,180,895	23,068,014
Total liabilities and shareholders’ equity	$29,939,033	$27,019,201

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
Statement Condensed Balance Sheets Parenthetical [Line Items]	'	'	'
Common stock, par value	$0.00	'	$0.00
Common stock, shares authorized	149,000,000	'	99,000,000
Common stock, shares issued	56,625,294	51,500,996	'
Common stock, shares outstanding	56,625,294	51,500,996	'

Condensed_Statements_of_Operat

Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		115 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Statement Condensed Statements Of Operations Unaudited [Line Items]	'	'	'	'	'
Revenues	$0	$0	$0	$0	$300,000
Expenses:	'	'	'	'	'
Research and development	1,276,507	2,378,917	3,905,338	6,567,086	22,165,450
Stock based compensation	156,277	33,887	500,351	382,611	9,216,363
General and administrative	985,107	1,004,181	2,542,794	2,647,301	15,227,541
Total expenses	2,417,891	3,416,985	6,948,483	9,596,998	46,609,354
Loss before other income (expense) and income taxes	-2,417,891	-3,416,985	-6,948,483	-9,596,998	-46,309,354
Interest income	3,667	1,858	14,310	4,867	362,053
Financing expense	0	0	0	-368,524	-397,294
Change in fair value of warrant liability	-1,379,217	2,777,500	-1,983,388	-5,018,224	-3,649,296
Loss before income taxes	-3,793,441	-637,627	-8,917,561	-14,978,879	-49,993,891
Income taxes	0	0	0	0	0
Net loss	-3,793,441	-637,627	-8,917,561	-14,978,879	-49,993,891
Deemed dividend on redemption of preferred stock	0	0	0	0	-2,092,500
Net loss attributable to common stock	($3,793,441)	($637,627)	($8,917,561)	($14,978,879)	($52,086,391)
Net loss per share, basic and diluted	($0.07)	($0.02)	($0.17)	($0.38)	($2.68)
Weighted average number of shares basic and diluted	55,307,906	40,329,306	53,289,854	39,260,253	19,438,888

Condensed_Statements_of_Shareh

Condensed Statements of Shareholders' Equity (Deficit) (Unaudited) (USD $)

Total

Common Stock 0.19 Per Share

Common Stock 0.32 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.55 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.73 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.96 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Promissory Note

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Retained Earnings

Common Stock 0.19 Per Share

Common Stock 0.32 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.55 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.73 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.96 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Common Stock 0.19 Per Share

Common Stock 0.32 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.55 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.73 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.96 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Common Stock 0.19 Per Share

Common Stock 0.32 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.55 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.73 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.96 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Common Stock 0.19 Per Share

Common Stock 0.32 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.55 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.73 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.96 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Common Stock 0.19 Per Share

Common Stock 0.32 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.55 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.73 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.96 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Balance at Feb. 24, 2004

$97

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$87

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Feb. 24, 2004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,256,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash

150

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

135

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

193,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-11,741

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-11,741

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2004

-11,494

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

222

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-11,741

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,450,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash

'

75,000

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

659

16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

74,341

49,984

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

387,000

154,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-246,004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-246,004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development

'

'

'

152,760

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

152,745

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

154,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2005

20,262

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

715

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

277,292

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-257,745

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2005

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,146,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-5,152,713

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,152,713

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development

'

'

'

'

'

694,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

69

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

693,931

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

694,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services

'

'

'

'

36,546

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,539

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

73,093

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash in private placements net of redemptions

549,400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

151

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

549,249

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash in private placements net of redemptions, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,510,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in connection with reverse merger

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

83

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-83

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in connection with reverse merger, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

825,124

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares cancelled in connection with the sale of Optical Molecular Imaging, Inc.

-65,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-206

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-64,794

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares cancelled in connection with the sale of Optical Molecular Imaging, Inc., shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,059,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

3,522

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,521

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,062

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

4,103,645

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,103,645

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2006

189,662

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

820

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,599,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,410,458

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2006

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,199,779

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-3,614,753

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,614,753

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash in private placements net of redemptions

4,892,486

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

353

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,892,133

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash in private placements net of redemptions, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,531,603

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

1,296,714

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,296,714

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51,111

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of warrant derivative liability

2,233,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,233,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2007

4,997,709

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,178

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,021,742

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-9,025,211

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2007

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,782,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-3,059,730

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,059,730

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development

'

'

'

'

'

'

424,000

65,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80

10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

423,920

64,990

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

Common stock issued for research and development, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

513,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

513,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2008

2,940,336

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,268

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,024,009

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-12,084,941

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2008

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,682,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-2,626,205

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,626,205

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

214,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

308,302

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

308,302

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants

462,748

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

197

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

462,551

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,970,992

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

11,814

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64,460

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-52,668

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2009

1,096,995

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,487

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,859,322

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-52,668

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-14,711,146

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2009

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,867,842

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-6,150,142

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,150,142

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services

'

'

'

'

'

'

'

'

54,000

8,156

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53,994

8,156

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

Common stock issued for services, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,000

7,694

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

26,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,495

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

745,697

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

745,697

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash net of offering costs

3,248,738

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

423

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,248,315

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash net of offering costs, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,230,910

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock and warrants issued for cash net of offering costs

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock and warrants issued for cash net of offering costs, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants in exchange for promissory note

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

270

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,399,730

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants in exchange for promissory note, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption of preferred stock for repayment of promissory note

3,307,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,092,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption of preferred stock for repayment of promissory note, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

297,156

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest on promissory note

-1,614

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,614

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2010

2,335,830

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,221

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,341,679

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-54,282

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-22,953,788

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2010

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22,213,602

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-5,719,903

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,719,903

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

382,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

1,190,133

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,190,120

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

131,537

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

388,379

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

38

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

388,341

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash net of offering costs

4,983,339

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

522

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,982,817

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash net of offering costs, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,219,768

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

67

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-67

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

667,077

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest on promissory note

-352

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-352

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption of promissory note

54,634

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

54,634

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2011

3,232,060

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,861

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31,902,890

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-28,673,691

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,613,984

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-14,495,139

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-14,495,139

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

496,007

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

496,007

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of warrant derivative liability

1,981,743

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,981,743

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants

3,201,920

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

230

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,201,690

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,295,334

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

20,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,498

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash net of offering costs

'

'

'

'

'

'

'

'

'

'

9,271,370

19,359,553

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

949

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,270,421

19,358,553

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

Common stock and warrants issued for cash net of offering costs, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,489,436

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

79

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-79

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

792,018

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of warrants

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

29

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-29

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of warrants shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

288,973

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock vested

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock vested, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,251

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2012

23,068,014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,150

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,231,694

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-43,168,830

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2012

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51,500,996

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-8,917,561

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-8,917,561

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

141,631

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

422,401

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

145,401

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

500,351

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,351

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants

5,407,382

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

293

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,407,089

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,926,072

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

141,631

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

141,616

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants in exchange for promissory note

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption of preferred stock for repayment of promissory note

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

131,228

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of warrants

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of warrants shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for license rights

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

74,997

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Common stock issued for license rights, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31,155

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued through controlled equity offering

'

'

'

'

'

'

'

'

'

'

'

'

'

404,208

2,013,116

1,752,331

736,423

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

17

77

64

28

'

'

'

'

'

'

'

'

'

'

'

'

'

404,191

2,013,039

1,752,267

736,395

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

0

Common stock issued through controlled equity offering, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

172,988

770,508

642,604

276,042

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Sep. 30, 2013

$25,180,895

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,663

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$77,261,623

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

($52,086,391)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Sep. 30, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

56,625,294

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Condensed_Statements_of_Shareh1

Condensed Statements of Shareholders' Equity (Deficit) (Parenthetical) (Unaudited) (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Sep. 30, 2013

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2005

Dec. 31, 2005

Dec. 31, 2008

Dec. 31, 2008

Dec. 31, 2010

Dec. 31, 2010

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Common Stock 0.19 Per Share

Common Stock 0.32 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.55 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.73 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.96 Per Share

Initial capitalization, per share

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash, per share

$0.00

'

'

'

'

'

$0.19

$0.32

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services, per share

'

'

'

'

$0.50

'

'

'

'

'

$0.90

$1.06

$2.41

'

'

'

'

'

'

Common stock issued for research and development, per share

'

'

'

'

$1

$0.99

'

'

$0.53

$0.65

'

'

'

'

'

'

'

'

'

Common stock issued for cash in private placements, per share

'

'

'

$1.50

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash, per share

'

$1.55

$1

'

'

'

'

'

'

'

'

'

'

$1.10

$2.10

'

'

'

'

Preferred stock and warrants issued for cash, per share

'

'

$10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued through controlled equity offering at an average, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.84

$2.57

$2.79

$2.90

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		115 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities:	'	'	'
Net loss	($8,917,561)	($14,978,879)	($49,993,891)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	35,682	34,331	110,967
Loss on disposal of assets	3,817	0	3,817
Change in fair value of warrant liability	1,983,388	5,018,224	3,649,296
Financing expense	0	368,524	397,294
Stock-based compensation	500,351	382,611	9,154,207
Common stock issued for services	0	0	98,703
Common stock issued for research and development	0	0	1,335,760
Changes in assets and liabilities:	'	'	'
Other assets	370,438	-501,714	-421,969
Accounts payable	-178,108	91,421	554,393
Accrued liabilities	147,330	397,899	512,786
Net cash used in operating activities	-6,054,663	-9,187,583	-34,598,637
Cash flows from investing activities:	'	'	'
Purchase of property and equipment	-37,877	-5,668	-193,569
Cash paid for sale of Optical Molecular Imaging, Inc.	0	0	-25,000
Net cash used in investing activities	-37,877	-5,668	-218,569
Cash flows from financing activities:	'	'	'
Proceeds from exercise of stock options	141,631	20,500	592,344
Proceeds from exercise of warrants	4,261,723	3,153,852	7,926,389
Payments on promissory note receivable	0	0	53,018
Proceeds from issuance of common stock and warrants, net of offering costs	4,906,078	9,371,370	51,899,857
Proceeds from issuance of preferred stock and warrants, net of offering costs	0	0	3,779,158
Net cash provided by financing activities	9,309,432	12,545,722	64,250,766
Increase in cash and cash equivalents	3,216,892	3,352,471	29,433,560
Cash and cash equivalents, beginning of period	26,216,668	6,653,168	0
Cash and cash equivalents, end of period	29,433,560	10,005,639	29,433,560
Supplemental cash flows disclosures:	'	'	'
Interest expense paid	0	0	0
Income taxes paid	0	0	0
Supplemental non-cash financing disclosures:	'	'	'
Exercise of warrants in exchange for promissory note	0	0	3,350,000
Redemption of preferred stock for repayment of promissory note	0	0	3,350,000
Deemed dividend on redemption of preferred stock	0	0	2,092,500
Warrant liability converted to additional paid-in capital upon exercise	1,145,659	1,944,688	3,127,404
Deposits used to acquire property and equipment	0	35,882	35,882
Deferred offering costs	0	0	182,599
Common stock issued for license rights	$75,000	$0	$75,000

Nature_of_Organization_and_Dev

Nature of Organization and Development Stage Operations	9 Months Ended
	Sep. 30, 2013
Nature of Organization and Development Stage Operations	'
	1. Nature of Organization and Development Stage Operations
	ImmunoCellular Therapeutics, Ltd. (the Company) is a development stage company that is seeking to develop and commercialize new therapeutics to fight cancer using the immune system.
	Since the Company’s inception on February 25, 2004, the Company has been primarily engaged in the acquisition of certain intellectual property, together with development of its product candidates and the recent clinical testing activities for one of its vaccine product candidates, and has not generated any recurring revenues. The Company’s lead product candidate, ICT-107, is in Phase II clinical development. The Company has two other candidates, ICT-140 and ICT-121, that each have investigational new drug (IND) applications for initiation of clinical development. The Company has sustained operating losses and, as of September 30, 2013, the Company had an accumulated deficit of $52,086,391. The Company expects to incur significant research, development and administrative expenses before any of its products can be launched and recurring revenues generated.
	Interim Results
	The accompanying condensed financial statements as of September 30, 2013 and for the three and nine months periods ended September 30, 2013 and 2012 and for the period from February 25, 2004 (inception) to September 30, 2013 are unaudited, but include all adjustments, consisting of normal recurring entries, which the Company’s management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2012 have been derived from the Company’s audited financial statements included in its Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission (SEC) on March 11, 2013.
	The financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with the Company’s audited financial statements in its Form 10-K for the year ended December 31, 2012. The Company’s operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Development Stage Enterprise – The Company is a development stage enterprise and is devoting substantially all of its present efforts to research and development. All losses accumulated since inception are considered part of the Company’s development stage activities.
	Liquidity – As of September 30, 2013, the Company had working capital of $28,767,993, compared to working capital of $25,832,869 as of December 31, 2012. The estimated cost of completing the development of any of our current vaccine product candidates and of obtaining all required regulatory approvals to market any of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances will be sufficient to fund our operations for at least the next twelve months, although there is no assurance that such proceeds will be sufficient.
	Cash and cash equivalents – The Company considers all highly liquid instruments with an original maturity of 90 days or less at acquisition to be cash equivalents. As of September 30, 2013 and December 31, 2012, the Company had $25,910,858 and $23,646,922, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments.
	Property and Equipment – Property and equipment are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
	Research and Development Costs – Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred.
	Stock Based Compensation – The Company records the cost for all share-based payment transactions in the Company’s financial statements.
	Stock option grants issued prior to March 31, 2011 to employees and officers and directors were valued using the Black-Scholes pricing model. Stock option grants made subsequent to March 31, 2011 were valued using the binomial lattice simulation model.
	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Nine months			Nine months
		Ended			Ended
		September 30,			September 30,
		2013			2012
	Risk-free interest rate		1.61	%		0.66	%
	Expected dividend yield		None			None
	Expected life		5.12 Years			4.42 Years
	Expected volatility		90.6	%		64.7	%
	Expected forfeitures		0	%		0	%
	The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the nine months ended September 30, 2013, the expected volatility is based upon the historical volatility of the Company’s common stock. For the nine months ended September 30, 2012, the expected volatility is based on market prices of traded options for comparable entities within our industry. Forfeitures have been estimated to be nil.
	The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.
	When options are exercised, our policy is to issue previously unissued shares of common stock to satisfy share option exercises. As of September 30, 2013, the Company had approximately 56,617,706 million shares of authorized but unissued common stock.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.
	Income Taxes – The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of September 30, 2013 and December 31, 2012, the Company fully reserved its deferred tax assets. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2012, 2011 and 2010 remain open for possible review.
	Fair Value of Financial Instruments – The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant derivative liability is estimated using the Binomial Lattice option valuation model.
	Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1—quoted prices in active markets for identical assets or liabilities
	Level 2—quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3—inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.
	Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.
	Basic and Diluted Loss per Common Share – Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation if the effect would be antidilutive. Common share equivalents which could potentially dilute earnings per share, and which were excluded from the computation of diluted loss per share, totaled 14,610,187 shares and 19,290,100 shares at September 30, 2013 and 2012 respectively.
	Recently Issued Accounting Standards – In June 2011, the Financial Accounting Standards Board (FASB) issued ASU No. 2011-5, which amends the Comprehensive Income Topic of the ASC. The ASU eliminates the option to present the components of other comprehensive income as part of the statement of changes in shareholders’ equity, and instead requires consecutive presentation of the statement of net income and other comprehensive income either in a continuous statement of comprehensive income or in two separate but consecutive statements. ASU No. 2011-5 became effective for interim and annual periods beginning after December 15, 2011. In February 2013, the FASB issued ASU No. 2013-02, which further amends the Comprehensive Income Topic of the ASC. This amendment requires entities to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount is being reclassified in its entirety to net income. This standard became effective for periods beginning after December 15, 2012. The adoption of these ASU’s did not have a material impact on the Company’s results of operations, financial condition or liquidity.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities Exchange Commission (the SEC) did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2013
Property and Equipment	'
	3. Property and Equipment
	Property and equipment consist of the following:
		September 30,			December 31,
		2013			2012
	Computers	$	58,375		$	23,192
	Research equipment		120,505			128,381
			178,880			151,573
	Accumulated depreciation		(104,213	)		(75,284	)
		$	74,667		$	76,289
	Depreciation expense was $13,998 and $11,443 for the three months ended September 30, 2013 and 2012, respectively. Depreciation expense was $35,682 and $34,331 for the nine months ended September 30, 2013 and 2012, respectively. Depreciation expense was $110,967 for the period from February 25, 2004 (date of inception) to September 30, 2013.

RelatedParty_Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2013
Related-Party Transactions	'
	4. Related-Party Transactions
	Cedars-Sinai Medical Center License Agreement
	Dr. John Yu, our Chief Scientific Officer and former interim Chief Executive Officer, is a neurosurgeon at Cedars-Sinai Medical Center (Cedars-Sinai). In November 2006, the Company entered into a license agreement with Cedars-Sinai under which the Company acquired an exclusive, worldwide license to its technology for use as cellular therapies, including cancer stem cell and dendritic cell-based vaccines for neurological disorders that include brain tumors and neurodegenerative disorders and other cancers. This technology is covered by a number of issued and pending U.S. and foreign patents and applications, and the term of the license will be until the last to expire of any patent claims that are issued covering this technology.
	As an upfront licensing fee, the Company issued Cedars-Sinai 694,000 shares of its common stock and paid Cedars-Sinai $62,000. Additional specified milestone payments will be required to be paid to Cedars-Sinai when the Company initiates patient enrollment in its first Phase III clinical trial and when it receives FDA marketing approval for its first product.
	The Company has agreed to pay Cedars-Sinai specified percentages of all of its sublicensing income and gross revenues from sales of products based on the licensed technology. To maintain its rights to the licensed technology, the Company must meet certain development and funding milestones. These milestones include, among others, commencing a Phase I clinical trial for a product candidate by March 31, 2007 and raising at least $5,000,000 in funding from equity or other sources by December 31, 2008. The Company satisfied the foregoing funding requirement in 2007 and commenced a Phase I clinical trial in May 2007, which was within the applicable cure period for the milestone requirement. Through December 31, 2009, the Company has paid Cedars-Sinai a total of $166,660 in connection with the Phase I clinical trial. The Company also was required to commence a Phase II clinical trial for a product candidate by December 31, 2008 and a waiver of this requirement was obtained from Cedars-Sinai (see Second Amendment below).
	On June 16, 2008, the Company entered into a First Amendment to Exclusive License Agreement (the Amendment) with Cedars-Sinai. The Amendment amended the License Agreement to include in the Company’s exclusive license from Cedars-Sinai under that agreement an epitope to CD133 and certain related intellectual property. This technology is covered by U.S. patent applications filed by both parties. Pursuant to the Amendment, the Company issued Cedars-Sinai 100,000 shares of the Company’s common stock as an additional license fee for the licensed CD133 epitope technology, which will be subject to the royalty and other terms of the License Agreement.
	On July 22, 2009, the Company entered into a Second Amendment to Exclusive License Agreement (the Second Amendment) with Cedars-Sinai to become effective August 1, 2009. The Second Amendment amended the License Agreement to revise the milestones set forth in the License Agreement that the Company must achieve in order to maintain its license rights under that agreement. The revised milestones include the replacement of a milestone that required commencement of a Phase II clinical trial for the Company’s first product candidate by no later than December 31, 2008 with milestones that require commencement of a Phase I clinical trial for the Company’s second product candidate by no later than June 30, 2010 and commencement of a Phase II clinical trial for one of the Company’s product candidates by no later than March 31, 2012.
	Effective March 23, 2010, the Company entered into a Third Amendment to Exclusive License Agreement (the Third Amendment) with Cedars-Sinai. The Third Amendment amended the License Agreement to revise the milestones set forth in the License Agreement that the Company must achieve in order to maintain its license rights under that agreement. The revised milestones include the replacement of a milestone that required commencement of a Phase I clinical trial for the Company’s second product candidate by no later than June 30, 2010 and commencement of a Phase II clinical trial for one of the Company’s product candidates by no later than March 31, 2012 with a requirement that by September 30, 2011 the Company either commence a Phase II clinical trial for its dendritic cell vaccine candidate or a Phase I clinical trial for its cancer stem cell vaccine candidate. The amendment also added a requirement that the Company obtain certain defined forms of equity or other funding in the amount of at least $2,500,000 by December 31, 2010 and a total of at least $5,000,000 by September 30, 2011. These funding requirements were fully satisfied as of June 30, 2011.
	Effective September 1, 2012, the Company entered into a new agreement with Cedars-Sinai whereby Cedars-Sinai provided research support for CD133 experiments in support of ICT-121. The agreement expired on September 19, 2013 and the Company made payments to Cedars-Sinai of $329,832. The Company is currently in negotiations with Cedars-Sinai to extend this research agreement.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies	'
	5. Commitments and Contingencies
	Sponsored Research Agreements
	In an effort to expand the Company’s intellectual property portfolio to use antigens to create personalized vaccines, the Company has entered into various intellectual property and research agreements. Those agreements are long-term in nature and are discussed below.
	Aptiv Solutions
	The Company has contracted with Aptiv Solutions to provide certain services related to the Company’s ICT-107 Phase II trial. The original agreement was entered into in August of 2010 and provided for estimated payments of approximately $3 million for services through September 2013. Subsequently, the Company and Aptiv entered into three contract amendments. Under the first amendment, effective January 20, 2011, Aptiv agreed to provide additional services in conjunction with the Phase II trial of ICT-107 for an additional fee of $469,807. The second amendment, effective February 4, 2012, extended the services to be provided by Aptiv and further increased the fees by $986,783. The second amendment also extended the term of the agreement to March 31, 2014. On January 11, 2013, the third amendment was finalized whereby the services were further extended and the fees were further increased by $608,201. The total aggregate fee pursuant to the original agreement and the three modifications is $5,078,169. As of September 30, 2013, the Company’s remaining obligation under the existing commitment is approximately $962,190.
	University of Pennsylvania
	On February 13, 2012, the Company entered into a Patent License Agreement with The Trustees of the University of Pennsylvania under which the Company acquired an exclusive, worldwide license relating to intellectual property for the production, use and cryopreservation of high-activity dendritic cell cancer vaccines, including ICT-107, its lead dendritic cell-based cancer vaccine candidate for the treatment of glioblastoma multiforme.
	Pursuant to the License Agreement, the Company paid an upfront licensing fee and will be obligated to pay annual license maintenance fees. In addition, the Company has agreed to make payments upon completion of specified milestones and to pay royalties of a specified percentage on net sales, subject to a specified minimum royalty, and sublicensing fees.
	The Johns Hopkins University Licensing Agreement
	On February 23, 2012, the Company entered into an Exclusive License Agreement, effective as of February 16, 2012, with The Johns Hopkins University (JHU) under which it received an exclusive, worldwide license to JHU’s rights in and to certain intellectual property related to mesothelin-specific cancer immunotherapies.
	Pursuant to the License Agreement, the Company agreed to pay an upfront licensing fee, payable half in cash and half in shares of its common stock, within 30 days of the effective date of the License Agreement and upon issuance of the first U.S. patent covering the subject technology. In addition, the Company has agreed to pay milestone license fees upon completion of specified milestones, customary royalties based on a specified percentage of net sales, sublicensing payments and annual minimum royalties.  Effective September 24, 2013, the Company entered into an Amendment No. 1 to the Exclusive License Agreement that updated certain milestones.
	The University of Pittsburgh Patent License Agreement
	On March 20, 2012, the Company entered into an Exclusive License Agreement with the University of Pittsburgh under which the Company has licensed intellectual property surrounding EphA2, a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies. The License Agreement grants a worldwide exclusive license to the intellectual property for ovarian and pancreatic cancers; and a worldwide non-exclusive license to the intellectual property for brain cancer. The Company intends to employ the intellectual property in the development and commercialization of ICT-140, a multivalent, dendritic cell-based vaccine for the treatment of ovarian cancer.
	Pursuant to the License Agreement, the Company agreed to pay an upfront nonrefundable and noncreditable licensing fee and nonrefundable and noncreditable maintenance fees due annually starting 12 months from the anniversary of the effective date of the License Agreement. In addition, the Company has agreed to make certain milestone payments upon completion of specified milestones and to pay customary royalties based on a specified percentage of net sales and sublicensing payments, as applicable.
	Torrey Pines
	On October 1, 2012, the Company entered into a Contract Services Agreement with Torrey Pines under which the Company has engaged Torrey Pines to determine the immunogenicity of certain peptides that are used in conjunction with the Company’s ICT-107 Phase IIb trial and in the development of ICT-140. The Company agreed to pay an upfront nonrefundable and noncreditable fee and is obligated to pay the remainder at the conclusion of the contract. On April 1, 2013, the Company and Torrey Pines expanded the scope of work to be completed by Torrey Pines under an additional Contract Services Agreement. This supplemental agreement provides for the Company to pay an upfront fee and additional fees at the conclusion of the contract.
	Cedars-Sinai Medical Center
	In connection with the Cedars-Sinai Medical Center License Agreement, the Company has certain commitments as described in Note 4.
	Employment Agreements
	The Company has one-year employment agreements with its management that provide for a base salary, bonus and stock option grants.  The aggregate annual base salary payable to this group is approximately $1,179,000 and the potential bonus is approximately $362,000.  Additionally, during the nine months ended September 30, 2013, the Company issued an aggregate of 489,000 stock options to its management at a weighted average exercise price of $2.66 that vest over a period of four years.
	Operating Lease
	The Company entered into a lease for new office space effective June 15, 2013 and continuing through August 31, 2016 at an initial monthly rental of $8,063. The monthly rental will increase by 3% on each anniversary date of the lease. Rent for the months of August and September 2013 was abated.  Rent expense was approximately $17,900 and $14,000 for the three months ended September 30, 2013 and 2012, respectively. Rent expense was approximately $55,000 and $40,000 for the nine months ended September 30, 2013 and 2012, respectively.
	Future minimum rentals under the operating lease are as follows:
	Years ending December 31,	Amount
	2013	$	24,189
	2014		97,724
	2015		100,905
	2016		68,432
	Total	$	291,250

Shareholders_Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2013
Shareholders Equity	'
	6. Shareholders’ Equity
	Common Stock
	In March 2010, the Company raised $1,654,686 (after commissions and offering expenses) from the sale of 1,740,000 shares of common stock and warrants to purchase 696,000 shares of common stock at an exercise price of $1.15 per share, to various investors in a private placement. (See “Warrants and Warrant Liabilities” below.)
	In May 2010, the Company raised $2,716,308 (after commissions and offering expenses) from the sale of 2,490,910 shares of common stock and warrants to purchase 1,245,455 shares of common stock at an exercise price of $1.50 per share, to various investors in a private placement. (See “Warrants and Warrant Liabilities” below)
	In February 2011, the Company raised $7,460,129 (after commissions and offering expenses) from the sale of 5,219,768 shares of common stock and warrants to purchase 2,609,898 shares of common stock at an exercise price of $2.25 per share, to various investors in a private placement. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $1.55. The January and October 2012 underwritten public offering (see below) provided for the issuance of shares at prices that were less than $1.55. Accordingly, the exercise price of these warrants was adjusted to $1.87 and the number of warrants was proportionally increased to 2,823,670 net of exercises. (See “Warrants and Warrant Liabilities” below)
	In January 2012, the Company raised approximately $9,271,370 in an underwritten public offering, net of offering expenses of approximately $1.1 million, from the sale of 9,489,436 shares of common stock and warrants to purchase 4,744,718 shares of common stock at an exercise price of $1.41 per share, to various investors in an underwritten public offering. The warrants have a term of 60 months from the date of issuance. The warrants do not contain any features (such as net cash settlement or anti-dilution features) that would preclude the Company from accounting for these warrants as equity. Accordingly, the warrants are accounted for as equity.
	In October 2012, the Company raised $19,359,553 in an underwritten public offering, net of offering expenses of approximately $1.6 million, from the sale of 10,000,000 shares of common stock and warrants to purchase 4,500,000 shares of common stock at an exercise price of $2.65 per share, to various investors in an underwritten public offering. The warrants have a term of 60 months from the date of issuance. The warrants do not contain any features (such as net cash settlement or anti-dilution features) that would preclude the Company from accounting for these warrants as equity. Accordingly, the warrants are accounted for as equity.
	Controlled Equity Offering
	On April 18, 2013, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the Sales Agreement) with Cantor Fitzgerald & Co., as agent (Cantor), pursuant to which the Company may offer from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $25.0 million (of which only $17.0 million is currently registered for offer and sale). Under the Sales Agreement, Cantor may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act, as amended, including sales made directly on the NYSE MKT, on any other existing trading market for our common stock or to or through a market maker. The Company may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by us from time to time. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. Cantor will receive a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and the Company has agreed to provide Cantor with customary indemnification and contribution rights. The Company will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement.  On April 22, 2013, NYSE MKT approved the listing of 10,593,220 shares of our common stock in connection with the Sales Agreement. Through September 30, 2013, we sold 1,862,142 shares of our common stock under the Sales Agreement that resulted in proceeds to the Company of approximately $4,906,078, less offering expenses of approximately $338,000.  As of September 30, 2013, aggregate gross sales for additional common stock of approximately $11,754,071 remained available under the Sales Agreement.
	Stock Options
	In February 2005, the Company adopted an Equity Incentive Plan (the Plan). Pursuant to the Plan, a committee appointed by the Board of Directors may grant, at its discretion, qualified or nonqualified stock options, stock appreciation rights and may grant or sell restricted stock to key individuals, including employees, nonemployee directors, consultants and advisors. Option prices for qualified incentive stock options (which may only be granted to employees) issued under the plan may not be less than 100% of the fair market value of the common stock on the date the option is granted (unless the option is granted to a person who, at the time of grant, owns more than 10% of the total combined voting power of all classes of stock of the Company; in which case the option price may not be less than 110% of the fair market value of the common stock on the date the option is granted). Option prices for nonqualified stock options issued under the Plan are at the discretion of the committee and may be equal to, greater or less than fair market value of the common stock on the date the option is granted. The options vest over periods determined by the Board of Directors and are exercisable no later than ten years from date of grant (unless they are qualified incentive stock options granted to a person owning more than 10% of the total combined voting power of all classes of stock of the Company, in which case the options are exercisable no later than five years from date of grant). Initially, the Company reserved 6,000,000 shares of common stock for issuance under the Plan. On October 24, 2011, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 8,000,000 shares. On September 20, 2013, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 12,000,000 shares. Options to purchase 3,852,655 common shares have been granted under the Plan and are outstanding as of September 30, 2013. As of September 30, 2013, there were 5,644,347 options available for issuance under the Plan.
	The following is a summary of stock option grants issued outside the Plan:
	In January 2007, the Company granted an option to purchase 1,500,000 shares of its common stock at an exercise price of $1.10 per share to the Chairman of the Company’s Scientific Advisory Board.
	In November 2006, the Company granted an option to purchase 300,000 shares of its common stock at an exercise price of $1.00 per share to an affiliate of the Company’s then Chairman of the Board.
	In November 2006, the Company granted an option to purchase 5,933,424 shares of its common stock at an exercise price of $1.00 per share to a Board member in connection with the Cedars-Sinai license acquisition.
	The following table summarizes stock option activity for the Company during the nine months ended September 30, 2013:
		Options			Weighted			Weighted		Aggregate
					Average			Average		Intrinsic
					Exercise			Remaining		Value
					Price			Contractual
								Term
	Outstanding December 31, 2012	10,581,194			$	1.16			0			0
	Granted	847,287				2.67			0			0
	Exercised	(422,401	)			1.33			0			0
	Forfeited or expired	(120,000	)			1.77			0			0
	Outstanding September 30, 2013	10,886,080			$	1.34			3.74		$	13,830,748
	Vested or expected to vest at September 30, 2013	8,806,043			$	1.06			2.98		$	13,394,524
	As of September 30, 2013, the total unrecognized compensation cost related to unvested stock options amounted to $2,641,357, which will be amortized over the weighted-average remaining requisite service period of approximately 22 months.
	Warrants
	In connection with the March 2010 common stock private placement, the Company issued to the investors warrants to purchase 696,000 shares of the Company’s common stock at $1.15 per share. The warrants had a term of 26 months from the date of issuance. As of September 30, 2013, these warrants have been fully exercised.
	In connection with the May 2010 common stock private placement, the Company issued to the investors warrants to purchase 1,287,733 shares of the Company’s common stock at $1.50 per share. The warrants have a term of 36 months from the date of issuance. As of September 30, 2013 these warrants have been fully exercised, except for warrants to purchase 4,000 shares of the Company’s common stock that expired. (See Warrant Liabilities below.)
	In connection with the sale of Preferred Stock in May 2010, the Company issued warrants to purchase 1,350,000 shares of common stock at an exercise price of $2.50. The warrants have a term of five-years from the date of issuance. As of September 30, 2013, warrants to purchase 1,290,996 shares of the Company’s common stock at $2.50 remain outstanding related to this private placement. (See “Warrant Liability” below.)
	In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,818,675 shares of the Company’s common stock at $2.25 per share. The warrants have a five-year term from the date of issuance and contain a provision that provides for an adjustment to the exercise price in the event the Company completes an equity financing at a per share price of its common stock that is less than $1.55. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,670 net of exercises. As of September 30, 2013, warrants to purchase 2,823,670 shares of the Company’s common stock remain outstanding related to this private placement. (See “Warrant Liability” below.)
	In connection with the January 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,744,718 shares of the Company’s common stock at $1.41 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of September 30, 2013, warrants to purchase 1,900,079 shares of the Company’s common stock remain outstanding relating to this public offering.
	In connection with the October 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,500,000 shares of the Company’s common stock at $2.65 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of September 30, 2013, warrants to purchase 4,480,750 shares of the Company’s common stock remain outstanding relating to this public offering.
	Warrant Liability
	The Company’s warrant liability is adjusted to fair value each reporting period and is influenced by several factors including the price of the Company’s common stock as of the balance sheet date. On September 30, 2013, the price per share of Company’s common stock was $2.57 per share compared to $1.92 per share at December 31, 2012 and $2.81 per share on September 30, 2012.
	In connection with the March 2010 common stock private placement, the Company issued to the investors warrants to purchase 696,000 shares of the Company’s common stock at $1.15 per share. Of the total proceeds from the March 2010 common stock private placement, $257,520 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that future common stock issuances are made at a price less than $1.00. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability was adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. Prior to 2011, the Company had concluded that Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the lattice simulation model, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 1.00%, and (iv) contractual life of 26 months.  During the year ended December 31, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. During the six months ended June 30, 2012, the remaining warrants were fully exercised; however, the Company recognized an expense of $45,570 as the Company revalued the warrants at the date of exercise.  For the three and nine months ended September 30, 2012, the Company recorded a charge to other expense of nil and $745,500, respectively.
	In connection with the May 2010 common stock private placement, the Company issued to the investors warrants to purchase 1,287,773 shares of the Company’s common stock at $1.50 per share. Of the total proceeds from the May 2010 common stock private placement, $834,455 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that future common stock issuances are made at a price less than $1.00. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. Prior to 2011, the Company had concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the binomial lattice simulation model, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 1.375%, and (iv) contractual life of 36 months. Effective January 1, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. For the three months ended September 30, 2012, the Company recorded a credit to other income of $745,778 and for the nine months ended September 30, 2012, the Company recorded a charge to other expense of $1,181,075. During the six months ended June 30, 2013, the remaining warrants were fully exercised; however, the Company recognized a credit to other income of $403,665 as the Company revalued the warrants at the date of exercise.  For the three and nine months ended September 30, 2013, the Company recorded a charge to other expense of nil and $583,134, respectively.
	In connection with the sale of Preferred Stock in 2010, the Company vested warrants to purchase 1,350,000 shares of the Company’s common stock at an exercise price of $2.50 per share. Of the total proceeds from the May 2010 preferred stock sale, $5,710,500 was allocated to the freestanding warrants associated with the units based upon the fair value of these warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant may be settled for cash in connection with a change of control with a private company. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period and any change in value is recognized in the statement of operations. Prior to 2011, the Company concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the Monte Carlo or binomial lattice simulation models, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 2.50%, and (iv) contractual life of 60 months. Effective January 1, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. For the three months ended September 30, 2012, the Company recorded a credit to other income of $718,720 and for the nine months ended September 30, 2012, the Company recorded a charge to other expense of $732,750. As of September 30, 2013, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 70%; (iii) risk free rate of 0.24% and (iv) expected term of 1.59 years. For the three and nine months ended September 30, 2013, the Company recorded a charge to other expense of $348,569 and $345,987, respectively. As of September 30, 2013, the carrying value of the warrant liability is $934,681.
	In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,818,675 shares of the Company’s common stock at $2.25 per share. Of the total proceeds from the February 2011 common stock private placement, $2,476,790 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Binomial lattice model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $1.55. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,670 net of exercises. The Company recorded a charge to financing expense of $397,294 to reflect the issuance of the additional warrants. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. The Company initially valued these warrants using a binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 146%; (iii) risk free rate of 1.96% and (iv) expected term of 5 years. Based upon those calculations, the Company calculated the initial valuation of the warrants to be $2,476,790. For the three months ended September 30, 2012, the Company recorded a credit to other income of $1,313,003 and for the nine months ended September 30, 2012, the Company recorded a charge to other expense of $2,727,643, As of September 30, 2013, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 73%; (iii) risk free rate of 0.45% and (iv) expected term of 2.39 years. For the three and nine months ended September 30, 2013, the Company recorded a charge to other expense of $1,030,649 and $1,054,268, respectively. As of September 30, 2013, the carrying value of the warrant liability is $2,755,928.
	For the three and nine months ended September 30, 2013, the expected volatility is based upon the historical volatility of the Company’s stock. For the three and nine months ended September 30, 2012, the expected volatility is based on market prices of traded options for comparable entities within our industry.
	The following reconciliation of the beginning and ending balances for all warrant liabilities measured at fair market value on a recurring basis using significant unobservable inputs (level 3) during the period ended September 30, 2013 and 2012:
		September 30,				September 30,
		2013				2012
	Balance – January 1	$		2,852,880		$	2,157,408
	Issuance of warrants and effect of repricing			0			368,524
	Exercise of warrants			(1,145,659	)		(1,944,688	)
	(Gain) or loss included in earnings			1,983,388			5,018,224
	Transfers in and out/or out of Level 3			—			—
	Balance – September 30	$		3,690,609		$	5,599,468

401K_Profit_Sharing_Plan

401(K) Profit Sharing Plan	9 Months Ended
	Sep. 30, 2013
401(k) Profit Sharing Plan	'
	7. 401(k) Profit Sharing Plan
	During 2011, the Company adopted a Profit Sharing Plan that qualifies under Section 401(k) of the Internal Revenue Code. Contributions to the plan are at the Company’s discretion. The Company did not make any matching contributions during the three and nine months ended September 30, 2013 or September 30, 2012.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Taxes	'
	8. Income Taxes
	Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards and stock-based compensation.
	As of September 30, 2013, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with its deferred tax assets. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset.
	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:
		September 30,				September 30,
		2013				2012
	Income tax benefit at the federal statutory rate		-34		%			-34		%
	State income tax benefit, net of federal tax benefit		-6		%			-6		%
	Change in fair value of warrant liability		9		%			14		%
	Change in valuation allowance for deferred tax assets		31		%			26		%
	Total		0		%			0		%
		September 30,				December 31,
		2013				2012
	Net operating loss carryforwards	$		15,759,274			$		12,821,749
	Stock-based compensation			1,931,443					1,796,954
	Less valuation allowance			(17,690,717	)				(14,618,703	)
	Net deferred tax asset	$		0			$		—
	As of September 30, 2013 and December 31, 2012, the Company had federal and California income tax net operating loss carryforwards of approximately $38 million. These net operating losses will begin to expire in 2022 and 2016, respectively, unless previously utilized.
	Section 382 of the Internal Revenue Code can limit the amount of net operating losses which may be utilized if certain changes to a company’s ownership occur. While the Company underwent an ownership change in 2012 as defined by Section 382 of the Internal Revenue Code, management estimated that the Company had not incurred any limitations on its ability to utilize its net operating losses under Section 382 of the Internal Revenue Code during 2012. The Company may incur limitations in the future if there is a change in ownership.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events	'
	9. Subsequent Events
	Warrant Exercises
	Subsequent to September 30, 2013, certain warrant holders exercised 198,550 warrants for cash and the Company received $279,956.
	Stock Option Exercises
	Subsequent to September 30, 2013, the Company issued 18,157 shares of common stock upon the cashless exercise of stock options to purchase 24,000 shares of common stock.  Additionally, the Company issued 267,387 shares of common stock as a result of the exercise of stock options and the Company received cash proceeds of $66,847.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Development Stage Enterprise	'
	Development Stage Enterprise – The Company is a development stage enterprise and is devoting substantially all of its present efforts to research and development. All losses accumulated since inception are considered part of the Company’s development stage activities.
Liquidity	'
	Liquidity – As of September 30, 2013, the Company had working capital of $28,767,993, compared to working capital of $25,832,869 as of December 31, 2012. The estimated cost of completing the development of any of our current vaccine product candidates and of obtaining all required regulatory approvals to market any of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances will be sufficient to fund our operations for at least the next twelve months, although there is no assurance that such proceeds will be sufficient.
Cash and Cash Equivalents	'
	Cash and cash equivalents – The Company considers all highly liquid instruments with an original maturity of 90 days or less at acquisition to be cash equivalents. As of September 30, 2013 and December 31, 2012, the Company had $25,910,858 and $23,646,922, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments.
Property and Equipment	'
	Property and Equipment – Property and equipment are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
Research and Development Expenses	'
	Research and Development Costs – Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred.
Stock Based Compensation	'
	Stock Based Compensation – The Company records the cost for all share-based payment transactions in the Company’s financial statements.
	Stock option grants issued prior to March 31, 2011 to employees and officers and directors were valued using the Black-Scholes pricing model. Stock option grants made subsequent to March 31, 2011 were valued using the binomial lattice simulation model.
	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Nine months			Nine months
		Ended			Ended
		September 30,			September 30,
		2013			2012
	Risk-free interest rate		1.61	%		0.66	%
	Expected dividend yield		None			None
	Expected life		5.12 Years			4.42 Years
	Expected volatility		90.6	%		64.7	%
	Expected forfeitures		0	%		0	%
	The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the nine months ended September 30, 2013, the expected volatility is based upon the historical volatility of the Company’s common stock. For the nine months ended September 30, 2012, the expected volatility is based on market prices of traded options for comparable entities within our industry. Forfeitures have been estimated to be nil.
	The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.
	When options are exercised, our policy is to issue previously unissued shares of common stock to satisfy share option exercises. As of September 30, 2013, the Company had approximately 56,617,706 million shares of authorized but unissued common stock.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.
Income Taxes	'
	Income Taxes – The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of September 30, 2013 and December 31, 2012, the Company fully reserved its deferred tax assets. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2012, 2011 and 2010 remain open for possible review.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments – The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant derivative liability is estimated using the Binomial Lattice option valuation model.
	Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1—quoted prices in active markets for identical assets or liabilities
	Level 2—quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3—inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.
Use of Estimates	'
	Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.
Basic and Diluted Loss per Common Share	'
	Basic and Diluted Loss per Common Share – Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation if the effect would be antidilutive. Common share equivalents which could potentially dilute earnings per share, and which were excluded from the computation of diluted loss per share, totaled 14,610,187 shares and 19,290,100 shares at September 30, 2013 and 2012 respectively.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards – In June 2011, the Financial Accounting Standards Board (FASB) issued ASU No. 2011-5, which amends the Comprehensive Income Topic of the ASC. The ASU eliminates the option to present the components of other comprehensive income as part of the statement of changes in shareholders’ equity, and instead requires consecutive presentation of the statement of net income and other comprehensive income either in a continuous statement of comprehensive income or in two separate but consecutive statements. ASU No. 2011-5 became effective for interim and annual periods beginning after December 15, 2011. In February 2013, the FASB issued ASU No. 2013-02, which further amends the Comprehensive Income Topic of the ASC. This amendment requires entities to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount is being reclassified in its entirety to net income. This standard became effective for periods beginning after December 15, 2012. The adoption of these ASU’s did not have a material impact on the Company’s results of operations, financial condition or liquidity.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities Exchange Commission (the SEC) did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Stock Options Grants	'
	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Nine months			Nine months
		Ended			Ended
		September 30,			September 30,
		2013			2012
	Risk-free interest rate		1.61	%		0.66	%
	Expected dividend yield		None			None
	Expected life		5.12 Years			4.42 Years
	Expected volatility		90.6	%		64.7	%
	Expected forfeitures		0	%		0	%

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Components of Property and Equipment	'
	Property and equipment consist of the following:
		September 30,			December 31,
		2013			2012
	Computers	$	58,375		$	23,192
	Research equipment		120,505			128,381
			178,880			151,573
	Accumulated depreciation		(104,213	)		(75,284	)
		$	74,667		$	76,289

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2013
Future Minimum Rentals Under Operating Lease	'
	Future minimum rentals under the operating lease are as follows:
	Years ending December 31,	Amount
	2013	$	24,189
	2014		97,724
	2015		100,905
	2016		68,432
	Total	$	291,250

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Stock Options Activity	'
	The following table summarizes stock option activity for the Company during the nine months ended September 30, 2013:
		Options			Weighted			Weighted		Aggregate
					Average			Average		Intrinsic
					Exercise			Remaining		Value
					Price			Contractual
								Term
	Outstanding December 31, 2012	10,581,194			$	1.16			0			0
	Granted	847,287				2.67			0			0
	Exercised	(422,401	)			1.33			0			0
	Forfeited or expired	(120,000	)			1.77			0			0
	Outstanding September 30, 2013	10,886,080			$	1.34			3.74		$	13,830,748
	Vested or expected to vest at September 30, 2013	8,806,043			$	1.06			2.98		$	13,394,524
Summary of Carrying Value of Warrant Liability	'
	The following reconciliation of the beginning and ending balances for all warrant liabilities measured at fair market value on a recurring basis using significant unobservable inputs (level 3) during the period ended September 30, 2013 and 2012:
		September 30,				September 30,
		2013				2012
	Balance – January 1	$		2,852,880		$	2,157,408
	Issuance of warrants and effect of repricing			0			368,524
	Exercise of warrants			(1,145,659	)		(1,944,688	)
	(Gain) or loss included in earnings			1,983,388			5,018,224
	Transfers in and out/or out of Level 3			—			—
	Balance – September 30	$		3,690,609		$	5,599,468

Income_Taxes_Tables

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2013
Federal Statutory Income Tax Rate to Loss before Income Taxes	'
	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:
		September 30,				September 30,
		2013				2012
	Income tax benefit at the federal statutory rate		-34		%			-34		%
	State income tax benefit, net of federal tax benefit		-6		%			-6		%
	Change in fair value of warrant liability		9		%			14		%
	Change in valuation allowance for deferred tax assets		31		%			26		%
	Total		0		%			0		%
Deferred Tax Asset	'
		September 30,				December 31,
		2013				2012
	Net operating loss carryforwards	$		15,759,274			$		12,821,749
	Stock-based compensation			1,931,443					1,796,954
	Less valuation allowance			(17,690,717	)				(14,618,703	)
	Net deferred tax asset	$		0			$		—

Nature_of_Organization_and_Dev1

Nature of Organization and Development Stage Operations (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Nature Of Organization And Development Stage Operations (Textual) [Abstract]	'	'
Deficit accumulated during the development stage	$52,086,391	$43,168,830

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Schedule of stock options grants	'	'
Risk-free interest rate	1.61%	0.66%
Expected dividend yield	'	'
Expected life	'5 years 1 month 13 days	'4 years 5 months 1 day
Expected volatility	90.60%	64.70%
Expected forfeitures	0.00%	0.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Summary Of Significant Accounting Policies (Additional Textual) [Abstract]	'	'	'
Working capital	$28,767,993	'	$25,832,869
Original maturity of highly liquid instruments	'90 days	'	'
Certificates of deposit	25,910,858	'	23,646,922
Estimated useful lives of property and equipment	'generally three to five years	'	'
Shares authorized but unissued common stock	56,617,706	'	'
Tax benefit attributed to the stock-based compensation expense	$0	'	'
Shares excluded from the computation of diluted net loss per share	14,610,187	19,290,100	'
Computer Equipment	'	'	'
Summary of Significant Accounting Policies (Textual) [Abstract]	'	'	'
Computer and computer equipment depreciation period	'3 years	'	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Components of Property and Equipment	'	'
Property and equipment, gross	$178,880	$151,573
Accumulated depreciation	-104,213	-75,284
Property and equipment, net	74,667	76,289
Computer Equipment	'	'
Components of Property and Equipment	'	'
Property and equipment, gross	58,375	23,192
Research Equipment	'	'
Components of Property and Equipment	'	'
Property and equipment, gross	$120,505	$128,381

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended		115 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Property and Equipment (Textual) [Abstract]	'	'	'	'	'
Depreciation expense	$13,998	$11,443	$35,682	$34,331	$110,967

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	1 Months Ended	9 Months Ended
	Nov. 30, 2006	Sep. 30, 2013	Sep. 30, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Jun. 16, 2008
Related Party Transactions (Textual) [Abstract]	'	'	'	'	'	'	'
Common stock, shares issued	694,000	'	'	'	'	'	'
Payment for upfront licensing fee	$62,000	'	'	'	'	'	'
Funding from equity	'	'	'	'	'	5,000,000	'
Payment to related Party	'	'	'	'	166,660	'	'
Shares issued to related parties	'	'	'	'	'	'	100,000
Other funding to related parties	'	'	5,000,000	2,500,000	'	'	'
Expected final contract price	'	$329,832	'	'	'	'	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended			1 Months Ended			9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Aug. 31, 2016	Jan. 11, 2013	Feb. 29, 2012	Jan. 20, 2011	Sep. 30, 2013	Sep. 30, 2013
						Aptiv Solution	Aptiv Solution	Aptiv Solution	Aptiv Solution	Employment Agreement With Management
									ContractAmendments
Commitments And Contingencies Textual [Abstract]	'	'	'	'	'	'	'	'	'	'
Payments for services	'	'	'	'	'	'	'	'	$3,000,000	'
Company's remaining commitment obligation	'	'	'	'	'	'	'	'	962,190	'
Amendment additional fee	'	'	'	'	'	608,201	986,783	469,807	'	'
Total aggregate fee	'	'	'	'	'	'	'	'	5,078,169	'
Number of contract amendments	'	'	'	'	'	'	'	'	3	'
Extended agreement date	'	'	31-Mar-14	'	'	'	'	'	'	'
Period within effective date of License Agreement.	'	'	'30 days	'	'	'	'	'	'	'
Nonrefundable And Noncreditable License And Maintenance Fee	'	'	'12 months	'	'	'	'	'	'	'
Base salary	'	'	'	'	'	'	'	'	'	1,179,000
Discretionary cash bonus	0	0	0	0	'	'	'	'	'	362,000
Purchase of stock option	'	'	847,287	'	'	'	'	'	'	489,000
Exercise option price	'	'	$2.67	'	'	'	'	'	'	$2.66
Incentive stock option grant, period	'	'	'	'	'	'	'	'	'	'4 years
Lease monthly rent	'	'	'	'	8,063	'	'	'	'	'
Operating lease rent expense	$17,900	$14,000	$55,000	$40,000	'	'	'	'	'	'
Percentage of annual increase of monthly base rent	'	'	3.00%	'	'	'	'	'	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies (Detail) (USD $)	Sep. 30, 2013
Future Minimum Rentals Under the Operating Lease	'
2013	$24,189
2014	97,724
2015	100,905
2016	68,432
Total	$291,250

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Summary of stock option activity	'
Options outstanding, Beginning Balance	10,581,194
Purchase of stock option	847,287
Exercise of stock options, shares	-422,401
Options, Forfeited or expired	-120,000
Options outstanding, Ending Balance	10,886,080
Options, Vested or expected to vest	8,806,043
Weighted Average Exercise Price, Outstanding, Beginning Balance	$1.16
Weighted Average Exercise Price, Granted	$2.67
Weighted Average Exercise Price, Exercised	$1.33
Weighted Average Exercise Price, Forfeited or expired	$1.77
Weighted Average Exercise Price, Outstanding, Ending Balance	$1.34
Weighted Average Exercise Price, Vested or expected to vest	$1.06
Weighted Average Remaining Contractual Term, Outstanding	'3 years 8 months 27 days
Weighted Average Remaining Contractual Term, Vested or expected to vest	'2 years 11 months 23 days
Aggregate Intrinsic Value, Outstanding	$13,830,748
Aggregate Intrinsic Value, Vested or expected to vest	$13,394,524

Shareholders_Equity_Details1

Shareholders' Equity (Details1) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Summary of carrying value of warrant liability	'	'
Balance b January 1	$2,852,880	$2,157,408
Issuance of warrants and effect of repricing	0	368,524
Exercise of warrants	-1,145,659	-1,944,688
(Gain) or loss included in earnings	1,983,388	5,018,224
Transfers in and out/or out of Level 3	'	'
Balance b September 30	$3,690,609	$5,599,468

Shareholders_Equity_Details_Te

Shareholders' Equity (Details Textual) (USD $)

1 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

6 Months Ended

9 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

Apr. 18, 2013

Apr. 22, 2013

Oct. 31, 2012

Jan. 31, 2012

Feb. 28, 2011

31-May-10

Mar. 31, 2010

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Oct. 24, 2011

Feb. 28, 2005

Sep. 30, 2013

Apr. 18, 2013

Apr. 18, 2013

Jan. 31, 2007

Nov. 30, 2006

Nov. 30, 2006

Sep. 30, 2013

Feb. 28, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Feb. 28, 2011

Dec. 31, 2011

31-May-10

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2010

Sep. 30, 2013

Sep. 30, 2012

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Oct. 31, 2012

Sep. 30, 2013

Mar. 31, 2010

Jun. 30, 2012

Sep. 30, 2012

Oct. 31, 2012

Jan. 31, 2012

Feb. 28, 2011

Oct. 31, 2012

Jan. 31, 2012

Feb. 28, 2011

31-May-10

Mar. 31, 2010

Dec. 31, 2010

Sep. 30, 2013

Feb. 28, 2011

31-May-10

Mar. 31, 2010

Feb. 28, 2011

31-May-13

31-May-10

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2010

31-May-10

31-May-10

Cantor Fitzgerald & Co.

Cantor Fitzgerald & Co.

Cantor Fitzgerald & Co.

Chairman Of Companys Scientific Advisory Board

Affiliate Of Chairman

Board

Equity Incentive Plan

February

February

February

February

February

February

February

February

May

May

May

May

May

May

May

May

May

May

January

October

October

March

March

March

Maximum

Maximum

Maximum

Warrant

Warrant

Warrant

Warrant

Warrant

Warrant

Warrant

Warrant

Warrant

Warrant

Warrant

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Warranty Obligations

Warranty Obligations

Offer and sale

Binomial Lattice Simulation

Binomial Simulation

Binomial Simulation

Binomial Simulation

Binomial Simulation

Binomial Lattice Simulation

Binomial Lattice Simulation

Binomial Lattice Simulation

Binomial Lattice Simulation

Binomial Lattice Simulation

Binomial Lattice Simulation

February

February

May

May

Maximum

May

May

May

May

May

May

May

Previous Valuation Assumptions

Previous Valuation Assumptions

February

Binomial Lattice Simulation

Binomial Lattice Simulation

Binomial Simulation

Shareholders' Equity Textual [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from the common stock private placement

'

'

$19,359,553

$9,271,370

$7,460,129

$2,716,308

$1,654,686

'

'

'

'

'

'

'

'

'

'

'

'

$2,476,790

'

'

'

'

'

'

'

$834,455

'

'

'

'

'

'

'

'

'

'

'

'

$257,520

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of common stock and warrants , shares

'

'

10,000,000

9,489,436

5,219,768

2,490,910

1,740,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of common stock, shares

'

'

4,500,000

4,744,718

2,609,898

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,245,455

696,000

'

'

2,818,675

1,287,733

696,000

'

'

1,350,000

'

'

'

'

'

1,287,773

Common stock, price per share

'

'

'

$1.41

'

'

'

$2.57

$2.81

$1.92

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.55

'

'

$2.25

$1.50

$1.15

'

'

$2.25

$1.50

$1.15

$1.55

'

$2.50

$2.50

'

'

'

'

$1.50

Exercise option price

'

'

'

'

'

'

'

$2.67

'

'

'

'

'

'

'

$1.10

$1

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.55

$1.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjusted exercise price of warrants

'

'

$1.87

$1.87

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future common stock issuance price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'less than $1.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'less than $1.00

'

Number of warrants outstanding increased net of exercises

'

'

2,823,670

2,823,670

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise term investor relations agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'60 months

'60 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Public offering expenses

'

'

1,600,000

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

$2.65

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.65

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of fair market value of common stock

'

'

'

'

'

'

'

'not be less than 100%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of common stock voting rights held

'

'

'

'

'

'

'

'more than 10%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum percentage of fair market value of common stock

'

'

'

'

'

'

'

'less than 110%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum exercisable period of options

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum exercisable period of options if percentage of common stock voting rights held is more than ten percent

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized under the plan

'

'

'

'

'

'

'

12,000,000

'

'

8,000,000

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares granted and outstanding

'

'

'

'

'

'

'

10,886,080

'

10,581,194

'

'

'

'

'

'

'

'

3,852,655

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options available for issuance

'

'

'

'

'

'

'

5,644,347

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of stock option

'

'

'

'

'

'

'

847,287

'

'

'

'

'

'

'

1,500,000

300,000

5,933,424

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to unvested stock options

'

'

'

'

'

'

'

2,641,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average remaining requisite service period

'

'

'

'

'

'

'

'22 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Exercise Term Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'36 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'26 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Warrants Expired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Shares Purchased Private Placement Warrant

'

'

2,823,670

'

'

'

'

2,823,670

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,900,079

'

4,480,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,290,996

'

'

'

'

'

Warrants exercisable period after initial issuance

'

'

'

'5 years

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend yield rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

0.00%

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

0.00%

0.00%

'

'

Expected volatility rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

73.00%

'

'

'

146.00%

'

'

'

'

102.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

102.00%

'

'

'

'

'

'

'

'

'

70.00%

102.00%

'

'

Risk-free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.45%

'

'

'

1.96%

'

'

'

'

1.38%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

0.24%

2.50%

'

'

Contractual life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 4 months 21 days

'

'

'

'5 years

'

'

'

'

'36 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'26 months

'

'

'

'

'

'

'

'

'

'1 year 7 months 2 days

'60 months

'

'

Recognized expense on warrants exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,570

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of warrant liability credited to other income

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,030,649

1,313,003

'

'

'

'

'

'

'

'

'

'

'

745,778

403,665

'

'

'

'

'

'

'

745,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

718,720

'

'

'

'

Proceeds from warrant shares attributed to free standing warrants related party of investor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,710,500

'

'

'

'

'

'

'

Warrant liability carrying value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,755,928

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

934,681

'

'

'

'

'

Charge to financing expense

'

'

'

'

'

'

'

'

'

397,294

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial valuation of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,476,790

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock aggregate offering price

'

'

'

'

'

'

'

5,663

'

5,150

'

'

'

25,000,000

17,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commission rate

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Listing of shares of common stock in connection with Sales Agreement

'

10,593,220

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash, shares

'

'

'

'

'

'

'

'

'

'

'

'

1,862,142

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of common stock

'

'

'

'

'

'

'

'

'

'

'

'

4,906,078

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional common stock sales gross

'

'

'

'

'

'

'

'

'

'

'

'

11,754,071

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs

'

'

'

'

'

'

'

338,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shareholders' Equity (Additional Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charge to other expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,054,268

$2,727,643

'

'

'

'

$583,134

$1,181,075

'

$348,569

'

'

$345,987

$732,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

401k_Profit_Sharing_Plan_Detai

401(k) Profit Sharing Plan (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
401(k) Profit Sharing Plan (Textual) [Abstract]	'	'	'	'
Discretionary cash bonus	$0	$0	$0	$0

Income_Taxes_Details

Income Taxes (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Federal statutory income tax rate to loss before income taxes	'	'
Income tax benefit at the federal statutory rate	-34.00%	-34.00%
State income tax benefit, net of federal tax benefit	-6.00%	-6.00%
Change in fair value of warrant liability	9.00%	14.00%
Change in valuation allowance for deferred tax assets	31.00%	26.00%
Total	0.00%	0.00%

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Deferred Tax Asset	'	'
Net operating loss carryforwards	$15,759,274	$12,821,749
Stock-based compensation	1,931,443	1,796,954
Less valuation allowance	-17,690,717	-14,618,703
Net deferred tax asset	$0	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012
		Federal	Federal	California	California
Income Taxes (Additional Textual) [Abstract]	'	'	'	'	'
Net operating losses expiration date	'expire in 2022 and 2016	'	'	'	'
Income Taxes (Textual) [Abstract]	'	'	'	'	'
Income tax net operating loss carryforwards	'	$38	$38	$38	$38

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	9 Months Ended		12 Months Ended			115 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2010	Dec. 31, 2007	Dec. 31, 2006	Sep. 30, 2013
Subsequent Events (Textual) [Abstract]	'	'	'	'	'	'
Exercise of stock options, shares	422,401	'	'	'	'	'
Exercise of stock options	$141,631	$20,500	$26,500	$0	$3,522	$592,344
Subsequent Event	'	'	'	'	'	'
Subsequent Events (Textual) [Abstract]	'	'	'	'	'	'
Number of warrant exercised	198,550	'	'	'	'	198,550
Value of warrants exercised	279,956	'	'	'	'	'
Common stock issued for cash, shares	18,157	'	'	'	'	'
Cashless exercise of stock options to purchase common stock, shares	24,000	'	'	'	'	'
Exercise of stock options, shares	267,387	'	'	'	'	'
Exercise of stock options	$66,847	'	'	'	'	'